The Potential Benefit of Telmisartan to Protect Overweight Patients with COPD from the Acquisition of COVID-19.
作者信息
Kow Chia Siang, Hasan Syed Shahzad
机构信息
School of Postgraduate Studies, International Medical University, Kuala Lumpur, Malaysia.
Department of Pharmacy, University of Huddersfield, Huddersfield, UK.
出版信息
Obesity (Silver Spring). 2020 Nov;28(11):2035. doi: 10.1002/oby.22976. Epub 2020 Sep 23.
Abstract
摘要
相似文献
1
The Potential Benefit of Telmisartan to Protect Overweight Patients with COPD from the Acquisition of COVID-19.
Obesity (Silver Spring). 2020 Nov;28(11):2035. doi: 10.1002/oby.22976. Epub 2020 Sep 23.
2
Effect of angiotensin II blockers on the prognosis of COVID-19: a toxicological view.
Eur J Clin Microbiol Infect Dis. 2020 Oct;39(10):2001-2002. doi: 10.1007/s10096-020-03932-6. Epub 2020 Jun 16.
3
A potential protective role of losartan against coronavirus-induced lung damage.
Infect Control Hosp Epidemiol. 2020 Jun;41(6):752-753. doi: 10.1017/ice.2020.80.
4
RAAS blockers in hypertension posing a higher risk toward the COVID-19.
Dermatol Ther. 2020 Jul;33(4):e13501. doi: 10.1111/dth.13501. Epub 2020 Jun 16.
5
Telmisartan as tentative angiotensin receptor blocker therapeutic for COVID-19.
Drug Dev Res. 2020 Nov;81(7):768-770. doi: 10.1002/ddr.21679. Epub 2020 May 1.
6
Hypertension, the renin-angiotensin system, and the risk of lower respiratory tract infections and lung injury: implications for COVID-19.
Cardiovasc Res. 2020 Aug 1;116(10):1688-1699. doi: 10.1093/cvr/cvaa097.
7
Renin-angiotensin system and SARS-CoV-2 interaction: underlying mechanisms and potential clinical implications.
Gen Physiol Biophys. 2020 May;39(3):203-204. doi: 10.4149/gpb_2020019.
8
Increased ACE2 Expression in Bronchial Epithelium of COPD Patients who are Overweight.
Obesity (Silver Spring). 2020 Sep;28(9):1586-1589. doi: 10.1002/oby.22907. Epub 2020 Jul 31.
9
Home Treatment of Older People with Symptomatic SARS-CoV-2 Infection (COVID-19): A structured Summary of a Study Protocol for a Multi-Arm Multi-Stage (MAMS) Randomized Trial to Evaluate the Efficacy and Tolerability of Several Experimental Treatments to Reduce the Risk of Hospitalisation or Death in outpatients aged 65 years or older (COVERAGE trial).
Trials. 2020 Oct 13;21(1):846. doi: 10.1186/s13063-020-04619-1.
10
Time-critical administration of corticosteroid rescue therapy for COVID-19 pneumonitis in a ward-based patient with chronic obstructive pulmonary disease.
Br J Hosp Med (Lond). 2020 Jul 2;81(7):1-4. doi: 10.12968/hmed.2020.0372. Epub 2020 Jul 20.
引用本文的文献
1
Montelukast and Telmisartan as Inhibitors of SARS-CoV-2 Omicron Variant.
Pharmaceutics. 2023 Jul 5;15(7):1891. doi: 10.3390/pharmaceutics15071891.
本文引用的文献
1
Increased ACE2 Expression in Bronchial Epithelium of COPD Patients who are Overweight.
Obesity (Silver Spring). 2020 Sep;28(9):1586-1589. doi: 10.1002/oby.22907. Epub 2020 Jul 31.
2
Renin-Angiotensin-Aldosterone System Blockers and the Risk of Covid-19.
N Engl J Med. 2020 Jun 18;382(25):2431-2440. doi: 10.1056/NEJMoa2006923. Epub 2020 May 1.
3
Angiotensin II mediates angiotensin converting enzyme type 2 internalization and degradation through an angiotensin II type I receptor-dependent mechanism.
Hypertension. 2014 Dec;64(6):1368-1375. doi: 10.1161/HYPERTENSIONAHA.114.03743. Epub 2014 Sep 15.
4
Telmisartan reduced abdominal circumference and body weight with decreasing triglyceride level in patients with type 2 diabetes and metabolic syndrome.
Obes Res Clin Pract. 2010 Apr-Jun;4(2):e83-e162. doi: 10.1016/j.orcp.2009.12.003.
5
Telmisartan prevents weight gain and obesity through activation of peroxisome proliferator-activated receptor-delta-dependent pathways.
Hypertension. 2010 Apr;55(4):869-79. doi: 10.1161/HYPERTENSIONAHA.109.143958. Epub 2010 Feb 22.
Zotero 插件